APOA1 and atherosclerosis: As CSL-112 demonstrated an ability to induce cholesterol efflux from foam cells equally in patients with and without stable atherosclerosis, it thus became a subject of assessment in a randomized controlled study of a single 6 g apoA1 injection in 17 thousand individuals with MI (AEGIS II trial).